PD-1 knockout CAR T cells were also assessed against glioblastoma, hepatocellular, and K562 tumor cell lines and demonstrated enhanced anti-tumor activity, reduced exhaustion, and augmented killing power in Car T cells (136–138). This evidence concerns the gene PDCD1 and neoplasm.